U.S. markets closed

Cidara Therapeutics, Inc. (CDTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.1600+0.0300 (+1.41%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Engulfing Line (Bearish)

Engulfing Line (Bearish)

Previous Close2.1300
Open2.1200
Bid2.1800 x 1000
Ask2.2300 x 1400
Day's Range2.1200 - 2.2100
52 Week Range1.7600 - 4.4500
Volume195,251
Avg. Volume547,173
Market Cap104.306M
Beta (5Y Monthly)1.34
PE Ratio (TTM)N/A
EPS (TTM)-1.7310
Earnings DateFeb 25, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Crestone Joins Antimicrobials Working Group
    PR Newswire

    Crestone Joins Antimicrobials Working Group

    The Antimicrobials Working Group (AWG) announced today the addition of Crestone, Inc. (Crestone) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG's membership to 12 antimicrobial drug companies.

  • Cidara to Present at Mycology 2021 Conference
    GlobeNewswire

    Cidara to Present at Mycology 2021 Conference

    SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will virtually present highlights from pre-clinical through Phase 2 clinical trial data evaluating rezafungin, Cidara’s novel, once-weekly echinocandin, for the treatment and prevention of invasive fungal disease at the Mycology 2

  • What Type Of Returns Would Cidara Therapeutics'(NASDAQ:CDTX) Shareholders Have Earned If They Purchased Their Shares Five Years Ago?
    Simply Wall St.

    What Type Of Returns Would Cidara Therapeutics'(NASDAQ:CDTX) Shareholders Have Earned If They Purchased Their Shares Five Years Ago?

    Some stocks are best avoided. We really hate to see fellow investors lose their hard-earned money. Anyone who held...